The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.
Arnoud J. Templeton
Honoraria - Janssen
Aurelius Gabriel Omlin
Employment or Leadership Position - The Institute of Cancer Research
Carmel Jo Pezaro
Employment or Leadership Position - The Institute of Cancer Research
Thian San Kheoh
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Raya Leibowitz-Amit
No relevant relationships to disclose
Francisco Emilio Vera-Badillo
No relevant relationships to disclose
Ian Tannock
No relevant relationships to disclose
Gerhardt Attard
Employment or Leadership Position - Institute of Cancer Research
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Other Remuneration - Janssen
Eitan Amir
No relevant relationships to disclose
Johann Sebastian De Bono
Employment or Leadership Position - The Institute of Cancer Research
Consultant or Advisory Role - Johnson & Johnson
Honoraria - Johnson & Johnson